Sep 20, 2021 7:00am EDT Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
Sep 09, 2021 11:46am EDT Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference
Sep 09, 2021 7:00am EDT Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman
Sep 07, 2021 7:30am EDT Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
Aug 11, 2021 7:00am EDT Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant
Aug 09, 2021 7:00am EDT Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College
Jul 07, 2021 7:30am EDT Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
Jul 06, 2021 8:30am EDT Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19
Jun 17, 2021 7:00am EDT Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
Jun 03, 2021 7:00am EDT Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil
